Kazia Therapeutics (ASX:KZA) enrols first patient in paxalisib study at Dana-Farber

Retrieved on: 2021-06-07 03:00:00

Tags for this article:

Click the tags to see associated articles and topics

Kazia Therapeutics (ASX:KZA) enrols first patient in paxalisib study at Dana-Farber. View article details on hiswai:

Excerpt

Health Care · ASX:KZA MCAP $168.3M. Jessica De Freitas Markets Reporter jessica.defreitas@ ...

Article found on: themarketherald.com.au